Project Grant R01AI185024
Award Date
2/24/25
Completion Date
1/31/30
Dollars Obligated
$578K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $870,800 Project Grant to the University of Maryland, Baltimore for the project "INNATE IMMUNE RECEPTOR DRIVEN PROGRAMMED NECROSIS IS COUPLED TO HYPER-SYNTHESIS OF INFLAMMATORY LIPID MEDIATORS IN HOST DEFENSE". The project aims to define the mechanism by which necroptotic cell death signals govern hyperproduction of inflammatory...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $658,273 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Massachusetts Medical School to study how the Herpes Simplex Virus 1 (HSV-1) activates and inhibits the NLRP1 inflammasome pathway, and to understand the role of NLRP1 in antiviral defense in human skin. The key objectives are to: 1) determine how the HSV-1 ICP0 protein activates stress-activated protein kinases and...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,019,807 Project Grant to the University of Missouri System on July 15, 2024. The grant's objective is to optimize Himar1 mutagenesis and expand targeted mutation capabilities in Ehrlichia chaffeensis and Anaplasma phagocytophilum, while also optimizing axenic media conditions to enable the continued replication of these tick-borne...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $785,511 Project Grant (R01AI182148) to the University of Chicago for the period of January 24, 2025 through December 31, 2029. The grant supports research under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop induced pluripotent stem cell (iPSC)-derived macrophages as a model to study the genetic basis of inter-individual variation in immune responses to pathogens. The university will...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,207,893 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Washington University in St. Louis, Missouri. The five-year grant, which runs from June 2024 to April 2029, will support research to investigate how latent gammaherpesvirus infections impact immune responses to subsequent pulmonary infections, as well as how the microbiome influences herpesvirus latency establishment and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,002,422 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore for the project "Mechanisms of Mucosal and Systemic Immunity to Vaccination and Infection with Enteric Pathogens in Children and Adults." The project aims to advance the understanding of protective immune responses against human-restricted enteric pathogens like...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $824,955 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine. The 5-year grant, running from February 2025 to January 2030, will support research to differentiate immune effector profiles in the skin after tick transmission of spotted fever group Rickettsia (SFGR) agents associated and not associated with spotted fever rickettsiosis (SFR). The...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the role of the protein ADAM9 in the immune response to SARS-CoV-2 infection and its impact on COVID-19 disease pathogenesis. The $190,058 award, spanning from December 2024 to November 2029, will be executed by the University of Massachusetts Medical School to investigate the ADAM9/MDA5...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,217,020 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Colorado-Denver. The five-year grant, active from May 2024 to March 2029, will fund research to understand the role of the CXCR4 chemokine receptor and integrins in central B cell tolerance and their impact on peripheral tolerance and autoimmune responses. The research aims to generate a deeper...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $244,440 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Albert Einstein College of Medicine in Bronx, New York. This funding will support a research project titled "Role of Cytolytic ZEB2+ Memory CD4+ T Cells in Protection Against Liver Stage Malaria." The project aims to use murine models to explore the kinetics, differentiation, functions, and protective...